U.S. Capital Markets Stock News

NYSE:AES
NYSE:AESRenewable Energy

AES (AES): One-Off Gain Drives Margin Improvement, Raises Questions on Earnings Sustainability

AES (AES) posted earnings growth of 9.7% over the past year, a step down from its striking 56.4% per year average over the past five years. Net profit margins improved to 7.6%, compared to 6.7% a year earlier. Shares currently trade at $14.22, notably below the estimated fair value of $19.28. With the company’s Price-To-Earnings ratio of 11x standing well below sector averages, investors will likely weigh discounted valuation against questions around the sustainability and quality of recent...
NasdaqCM:SNDL
NasdaqCM:SNDLPharmaceuticals

A Look at SNDL (NasdaqCM:SNDL) Valuation After Recent Earnings Show Higher Sales and Slimmer Net Losses

SNDL (NasdaqCM:SNDL) has released its third quarter and nine month earnings for 2025, revealing higher sales and a narrower net loss compared to the same periods last year. These updates are sparking fresh investor interest. See our latest analysis for SNDL. SNDL’s share price has been on a rollercoaster this year. After a rally earlier in the quarter, it’s taken a breather with a 27.7% drop over the past month and a 14.4% fall in the last week, despite the latest earnings showing meaningful...
NasdaqGM:RANI
NasdaqGM:RANIPharmaceuticals

Rani Therapeutics (RANI): Valuation in Focus After Landmark Chugai Deal and Breakthrough Clinical Data

Rani Therapeutics Holdings (RANI) just made headlines with a new licensing agreement with Chugai Pharmaceutical. This deal brings over $1 billion in potential revenue for its RaniPill technology and boosts its financial flexibility. See our latest analysis for Rani Therapeutics Holdings. Momentum around Rani Therapeutics Holdings has accelerated sharply, with a 1-month share price return of nearly 400% and year-to-date gains over 70%. This reflects investor excitement after its Chugai deal...